C. Langer

C. Obasaju, S. Feigenberg, B. Movsas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

C. Langer, J. Weiss, 2009, Current treatment options in oncology.

Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?

H. Choy, H. Wakelee, N. Saijo, 2008, Clinical lung cancer.

Phase I Study of Radical Thoracic Radiation, Weekly Irinotecan, and Cisplatin in Locally Advanced Non-small Cell Lung Carcinoma

M. Millenson, S. Litwin, S. Feigenberg, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I Trial of Concurrent Hyperfractionated Split Course Radiotherapy (HFx RT), Cisplatin (cDDP), and Paclitaxel in Patients with Recurrent, Previously Irradiated, or Treatment-Naïve Locally Advanced Upper Aerodigestive Malignancy

E. Horwitz, S. Litwin, J. Ridge, 2006, Cancer investigation.

E-47. Combined modality therapy in older patients with stage III NSCLC and limited SCLC

C. Langer, 2003 .

Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim report.

W. Curran, S. Litwin, B. Movsas, 2001, Clinical lung cancer.

The Emerging Role of Paclitaxel and Carboplatin in Non-Small Cell Lung Carcinoma

C. Langer, 1997 .

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Sharyn I. Katz, K. Elenitoba-Johnson, W. Hwang, 2019, JAMA oncology.

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

N. Hanna, P. Bunn, P. Ellis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

A. Troxel, L. Shulman, K. Schmitz, 2016, Lung cancer.

Radiotherapy Patterns of Care Study in Lung Carcinoma

D. Ettinger, R. Abrams, R. Munden, 2003 .

Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer.

C. Langer, 2006, Clinical lung cancer.

Warthin's Tumors and Their Relationship to Lung Cancer

C. Langer, K. Williams, C. K. White, 2015, Cancer investigation.

Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective.

C. Langer, Tianyu Li, V. Paralkar, 2008, Clinical Lung Cancer.

The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer.

C. Langer, 2001, Lung cancer.

Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.

M. Millenson, B. Movsas, C. Langer, 2000, Lung cancer.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

C. Gridelli, K. Syrigos, Y. Ohe, 2018, JAMA oncology.

Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303

A. Egloff, R. Seethala, Lin Wang, 2014, Clinical Cancer Research.

Adjuvant Therapy for Lung Cancer in the Elderly

C. Langer, J. Weiss, 2011 .

Efforts in Lung Cancer : Focus on Early-Stage Non – Small-Cell Lung Cancer comprehensive review

H. Choy, H. Wakelee, N. Saijo, 2011 .

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

H. Wakelee, J. Schiller, C. Langer, 2012, Lung cancer.

Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.

C. Langer, V. Hirsh, 2010, Lung cancer.

Skeletal Metastases: Optimal Management Today

C. Langer, John A. Kosteva, J. Kosteva, 2009 .

Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.

C. Langer, 2005, Clinical lung cancer.

Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.

M. Socinski, C. Langer, V. Hirsh, 2015, Clinical lung cancer.

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

M. Socinski, K. O'Byrne, T. Ciuleanu, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The surgical management of superior sulcus tumors: a retrospective review with long-term follow-up.

Hao Wang, A. Hanlon, W. Scott, 2005, The Annals of thoracic surgery.

Proceedings from the 14 th Annual Winter Lung Cancer Conference

C. Langer, G. Oxnard, 2017 .

Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

N. Hanna, P. Bunn, P. Ellis, 2005 .

2007 Highlights from: the 12th World Conference on Lung Cancer Seoul, South Korea; September 2-6, 2007

R. Herbst, D. Gandara, C. Langer, 2007 .

Reply to A.H. Fischer et al

E. Brambilla, J. Soria, C. Langer, 2011 .

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

J. Strausz, T. Mok, S. Novello, 2010 .

RADIATION THERAPY FOR SMALL-CELL LUNG CANCER

K. Rosenzweig, I. Chetty, L. Kestin, 2012 .

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.

M. Socinski, S. Dakhil, C. Langer, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Study of Capecitabine and Oxaliplatin in Combination With the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors

P. Engstrom, L. Weiner, C. Langer, 2008, American journal of clinical oncology.

A phase II trial of weekly paclitaxel and conventional radiotherapy for supratentorial glioblastoma multiforme: RTOG 96-02

B. Movsas, C. Langer, C. Scott, 1998 .

Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410

W. Curran, S. Hauser, W. Sause, 2000 .

Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.

P. O'dwyer, C. Langer, M. Graham, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small cell lung cancer: Clinical practice guidelines in oncology

Quynh-Thu Le, Renato Martins, Joe Y. Chang, 2006 .

Targeting Anemia in Patients with Lung Cancer

F. Hirsch, J. Crawford, C. Langer, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

David Harrington, D. Harrington, J. Krook, 2002, The New England journal of medicine.

Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience

J. Shrager, J. Cooper, C. Langer, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

M. von Mehren, D. Camidge, L. Chow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

C. Langer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC): Results of OPN-017

M. Millenson, S. Litwin, H. Borghaei, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy

M. Millenson, H. Borghaei, C. Langer, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer.

C. Langer, R. Lilenbaum, 2004, Seminars in oncology.

Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.

K. Rosenzweig, W. Curran, H. Choy, 2015, Practical radiation oncology.

Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients

Suzanne M. Miller, C. Lerman, B. Movsas, 2004, Psycho-oncology.

Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment

Suzanne M. Miller, C. Lerman, B. Movsas, 2004, Head & neck.

National Cancer Database report on cancer of the head and neck: 10‐Year update

K. Ang, R. Weber, J. Cooper, 2009, Head & neck.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

M. Socinski, H. Wakelee, C. Langer, 2018, Journal of thoracic disease.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

S. Ramalingam, C. Langer, R. Ionescu-Ittu, 2014, Lung cancer.

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

M. Socinski, Lisa I. Wang, C. Langer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting.

C. Langer, 2008, Clinical lung cancer.

Meaningful Subset Analyses Contribute to Optimal Patient Care

R. Gray, S. Ramalingam, J. Schiller, 2008 .

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

C. Langer, R. Mick, R. Cohen, 2019, JAMA oncology.

POSTOPERATIVE ADJUVANT THERAPY IN NON-SMALL-CELL LUNG CANCER

K. Rosenzweig, B. Movsas, R. Decker, 2010 .

First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

T. Clackson, A. Shaw, S. Gettinger, 2013 .

Novel Cytotoxic Agents in Combination with Radiation in the Management of Locally Advanced Non-Small Cell Lung Cancer: Focus on Pemetrexed and Nab-Paclitaxel [Abraxane]

C. Langer, 2011 .

Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.

C. Langer, R. Mick, R. Cohen, 2022, Clinical lung cancer.

Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

David M Jablons, Eric Holmgren, Roy S Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study

M. Socinski, K. O'Byrne, A. Szczesna, 2005 .

An update on North American randomized studies in non-small cell lung cancer.

P. Bunn, E. Vokes, J. Schiller, 1998, Seminars in oncology.

Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma

M. Feldman, C. Langer, S. Albelda, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Irinotecan in advanced lung cancer: focus on North American trials.

C. Langer, 2004, Oncology.

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

J. Krook, J. Schiller, C. Langer, 2001, Cancer.

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

Roy S Herbst, R. Herbst, C. Langer, 2002, Seminars in oncology.

Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

R. Herbst, K. Kelly, D. Gandara, 2020 .

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treated PI 3 K-Positive Patients with Stage IV Squamous Cell Lung Cancer ( Lung-MAP Sub-Study )

Jeffrey, Crawford, R. Herbst, 2019 .

The role of new agents in advanced non—small–cell lung carcinoma

C. Langer, 2000, Current oncology reports.

LBA4EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON–SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES

A. Shaw, S. Gettinger, R. Salgia, 2015 .

The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer.

Christopher U. Jones, A. Garden, R. Weber, 2021, Journal of geriatric oncology.

Commentary (Engstrom/Langer): Management of Cancer in the Elderly

P. Engstrom, C. Langer, Facp., 2006 .

Clinical Investigation : Thoracic Cancer Penetration of Recommended Procedures for Lung Cancer Staging and Management in the United States Over 10 Years : A Quality Research in Radiation Oncology Survey

R. Komaki, B. Movsas, C. Langer, 2013 .

An economic analysis of Radiation Therapy Oncology Group 94-10: cost-efficacy of concurrent vs. sequential chemoradiotherapy

W. Curran, H. Choy, R. Komaki, 2018, Journal of Radiation Oncology.

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

M. Socinski, C. Gridelli, Michael Thomas, 2021, Frontiers in Oncology.

Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer

C. Simone, A. Berman, C. Langer, 2017, Cancer.

Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.

W. Curran, S. Litwin, C. Langer, 1993, International journal of radiation oncology, biology, physics.

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

M. Socinski, Gregory Riely, R. Perez-soler, 2017, Clinical lung cancer.

O-49 Age-specific subanalysis of ECOG 1594: Fit elderly patietns (70–80 yrs) with NSCLC do as well as younger patients (<70)

M. Vangel, J. Schiller, C. Langer, 2003 .

Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study

M. Socinski, K. O'Byrne, C. Langer, 2005 .

The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer

C. Langer, John A. Kosteva, J. Kosteva, 2008, Current opinion in oncology.

LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

L. Paz-Ares, C. Langer, L. Terstappen, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

HER2 Expression in Salivary Gland Carcinomas

C. Langer, A. Colevas, P. Amrein, 2004, Clinical Cancer Research.

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

M. Socinski, R. Herbst, F. Hirsch, 2018 .

MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

M. Socinski, R. Herbst, F. Hirsch, 2017 .

Quality‐adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small‐cell Lung Cancer Receiving First‐line nab‐Paclitaxel/Carboplatin or Paclitaxel/Carboplatin

C. Langer, M. Botteman, V. Hirsh, 2018, Clinical lung cancer.

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

C. Langer, R. Cohen, C. Aggarwal, 2021, JAMA oncology.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410)

W. Curran, R. Komaki, S. Hauser, 2000 .

All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma

W. Yung, S. Phuphanich, C. Langer, 1997, Journal of Neuro-Oncology.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Edward S. Kim, C. Langer, J. Goldman, 2018, Front. Oncol..

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non–Small Cell Lung Cancer Receiving Sequential Treatment

C. Simone, C. Langer, R. Rengan, 2016, American journal of clinical oncology.

Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.

C. Simone, J. Bradley, S. Gettinger, 2019, Journal of Clinical Oncology.

24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

L. Sequist, H. Borghaei, S. Jalal, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.

Sharyn I. Katz, C. Simone, C. Langer, 2018, Current problems in diagnostic radiology.

Standards of care for anemia management in oncology

H. Choy, C. Langer, J. Glaspy, 2002, Cancer.

Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)

S. Novello, M. Dolled-Filhart, L. Paz-Ares, 2012 .

ACR Appropriateness Criteria s Postoperative Adjuvant Therapy in Non-Small Cell Lung Cancer

Joe Y. Chang, K. Rosenzweig, B. Movsas, 2014 .

Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and Herceptin (H) in HER2/neu (+) advanced NSCLC: Preliminary analysis

S. Adak, Douglas B. Johnson, A. Thor, 2000 .

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

Postoperative complications after combined neoadjuvant treatment of lung cancer.

W. Curran, C. Langer, S. Keller, 1993, The Annals of thoracic surgery.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Edward S. Kim, H. Groen, E. Smit, 2022, JTO clinical and research reports.

Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? a secondary analysis of RTOG 94-10

W. Curran, R. Komaki, W. Sause, 2001 .

Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC)

W. Curran, R. Komaki, W. Sause, 2000 .

Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.

W. Curran, A. Hanlon, L. Coia, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and lapatinib for the first‐line treatment of metastatic/recurrent head and neck squamous cell carcinoma

D. Hayes, W. Hwang, C. Langer, 2016, Cancer.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

N. Agarwal, D. Pfister, R. Mehra, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg / m 2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

N. Agarwal, D. Pfister, R. Mehra, 2012 .

Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax).

C. Langer, 2004, The oncologist.

Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.

D. Gandara, M. Edelman, R. Ozols, 1999, Seminars in oncology.

Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

L. Sequist, H. Borghaei, S. Jalal, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

Sharyn I. Katz, C. Langer, S. Yee, 2021, JCO precision oncology.

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.

C. Langer, R. Greenberg, J. Viallet, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.

C. Langer, N. Haas, N. Haas, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

A. Tafreshi, L. Paz-Ares, M. Pietanza, 2019, Annals of Oncology.

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

Sharyn I. Katz, K. Cengel, C. Langer, 2022, PloS one.

Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.

C. Langer, 2001, Oncology.

Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.

C. Langer, P. Loehrer, W. Tester, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of Efficacy of Topotecan in the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck: An Eastern Cooperative Oncology Group Trial (E3393)

B. Burkey, B. Murphy, C. Langer, 2001, American journal of clinical oncology.

Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)

L. Paz-Ares, C. Langer, A. Gualberto, 2007 .

Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP).

C. Langer, Y. Hei, R. Cook, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

D. Planchard, C. Faivre-Finn, S. Senan, 2021, Future oncology.

A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

R. Herbst, J. Bradley, K. Kelly, 2017 .

ACR Appropriateness Criteria s Radiation Therapy for Small-Cell Lung Cancer

Joe Y. Chang, K. Rosenzweig, I. Chetty, 2014 .

Clinical Studies Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN 8054 , a Small-Molecule Inhibitor of Aurora A Kinase

S. Tirrell, K. Venkatakrishnan, J. Tabernero, 2011 .

Radiotherapy (RT) patterns of care study (PCS) in lung carcinoma

D. Ettinger, R. Abrams, R. Munden, 2002 .

In reply [6]

B. Movsas, Colum J Smith, C. Langer, 2005 .

Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.

W. Curran, B. Movsas, C. Langer, 2001, International journal of radiation oncology, biology, physics.

ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.

K. Rosenzweig, R. Komaki, R. Feins, 2009, Journal of the American College of Radiology : JACR.

Durable Response and Improved CD8 T Cell Plasticity in Lung Cancer Patients After PD1 Blockade and JAK Inhibition

Darwin Q. Ye, E. Wherry, A. Minn, 2022, medRxiv.

M. Socinski, K. O'Byrne, T. Ciuleanu, 2008 .

Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer

C. Langer, T. Evans, S. Bagley, 2016 .

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Sharyn I. Katz, C. Langer, D. Sterman, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival

R. Weber, J. Cooper, A. Stewart, 2006, The Laryngoscope.

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.

C. Langer, M. Corradetti, N. Mitra, 2011, International journal of radiation oncology, biology, physics.

The Role of Tegafur/Uracil in Pulmonary Malignancy

C. Langer, 2012, Drugs.

Retreatment of recurrent head and neck cancer in a previously irradiated field.

J. Bourhis, C. Langer, Stuart J. Wong, 2012, Seminars in radiation oncology.

The global role of irinotecan in the treatment of lung cancer: 2003 update.

C. Langer, 2003, Oncology.

FDG PET Response by 3 Months Following Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer May be an Early Surrogate of Local Failure

W. Scott, S. Feigenberg, B. Movsas, 2007 .

Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report.

C. Langer, 2006, Supportive cancer therapy.

ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC).

P. Stephenson, J. Schiller, C. Langer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Anti–Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Therapies in the Treatment of Non-Small-Cell Lung Cancer

J. Soria, C. Langer, 2010 .

Is a cancer diagnosis a teachable moment for the patient’s relative who smokes?

C. Langer, F. Leone, R. Schnoll, 2013, Cancer Causes & Control.

Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer

J. Deasy, K. Cengel, S. Feigenberg, 2023, Clinical and translational radiation oncology.

Toxicities and Deaths From Intercurrent Disease Following Contemporary Postoperative Radiotherapy in Resected Non-Small-Cell Lung Cancer.

S. Singhal, K. Cengel, S. Feigenberg, 2022, Clinical lung cancer.

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

J. Lunceford, M. Ayers, L. Sequist, 2019, Journal of Thoracic Oncology.

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

A. Lanfranco, Kevin C. Ma, W. Hwang, 2022, JTO clinical and research reports.

Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241.

W. Curran, H. Choy, S. Swann, 2006, Journal of Clinical Oncology.

Radiotherapy patterns of care study in lung carcinoma.

D. Ettinger, R. Abrams, R. Munden, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Edward S. Kim, H. Groen, E. Smit, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross‐sectional survey

C. Langer, J. Mao, M. Schapira, 2015, Cancer.

Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.

André Rogatko, Louis M Weiner, R Katherine Alpaugh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

C. Langer, A. Vachani, R. Cohen, 2017, Lung cancer.

Lung cancer in the elderly.

A. Rossi, C. Gridelli, C. Langer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.

C. Gridelli, K. Kelly, F. Shepherd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.

G. Scagliotti, F. Hirsch, W. Franklin, 2003, Lung cancer.

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).

P. Postmus, T. Mok, C. Langer, 2013, Cancer treatment reviews.

Small cell lung cancer.

Renato Martins, Nithya Ramnath, Bruce E Johnson, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of N‐phosphonacetyl‐L‐aspartate, recombinant interferon‐alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck

S. Litwin, J. Ridge, C. Langer, 1998, Head & neck.

Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer.

C. Langer, C J Langer, 1999, Seminars in radiation oncology.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

E. Genden, T. Fojo, S. Bates, 2018, Journal of the National Cancer Institute.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Arijit Chakravarty, Hua Liu, Karthik Venkatakrishnan, 2011, Cancer research.

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

E. Helman, W. Hwang, A. Berman, 2020, Clinical Cancer Research.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Edward S. Kim, C. Obasaju, M. Socinski, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung.

D. Asch, K. Armstrong, C. Langer, 2012, Journal of oncology practice.

Gene signature of antigen processing and presentation machinery (APM) as highly predictive of response to checkpoint blockade in lung cancer and melanoma.

W. Hwang, C. Langer, S. Albelda, 2020 .

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

C. Langer, R. Mick, E. Carpenter, 2018, JCO precision oncology.

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

W. Curran, R. Jeraj, J. Bradley, 2017, Clinical lung cancer.

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

C. Langer, E. Carpenter, R. Cohen, 2017, Annals of translational medicine.

Clinicopathologic Features of Advanced Squamous NSCLC.

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

J. Crowley, J. Jett, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic Therapy for Mutation-Driven NSCLC.

C. Langer, Lova Sun, M. Marmarelis, 2021, Seminars in radiation oncology.

BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort

M. Prados, W. Curran, J. Knisely, 2021, Oncology.

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non–Small‐cell Lung Cancer

C. Langer, I. Blair, A. Vachani, 2017, Clinical lung cancer.

The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System

C. Langer, S. Albelda, E. Moon, 2017, Annals of the American Thoracic Society.

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Benjamin Movsas, Walter J Curran, Elizabeth Gore, 2011, Journal of the National Cancer Institute.

Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.

W. Curran, S. Litwin, C. Langer, 1996, The cancer journal from Scientific American.

Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?

C. Langer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary Adenoid Cystic Carcinoma of the Lung

C. Langer, J. Devlin, 2012 .

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

C. Langer, C. Watt, R. Mick, 2013, Clinical lung cancer.

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

C. Langer, C. Watt, R. Mick, 2013, Lung cancer.

Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.

C. Langer, 2012, Critical reviews in oncology/hematology.

Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.

L. Sequist, C. Langer, L. Horn, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Current management of brain metastases, with a focus on systemic options.

M. Mehta, C. Langer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and carboplatin in combination: phase I and phase II studies.

R. Ozols, C. Langer, P. Calvert, 1998, Seminars in oncology.

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.

C. Langer, M. Marmarelis, 2020, Clinical lung cancer.

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

W. Hwang, C. Langer, S. Albelda, 2020, Journal for ImmunoTherapy of Cancer.

Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.

W. Hwang, L. Shulman, C. Langer, 2022, Journal of Clinical Oncology.

The role of radiation therapy and chemotherapy in the management of airway tumors other than small-cell carcinoma and non-small-cell carcinoma.

B. Movsas, C. Langer, J. Kaminski, 2003, Chest surgery clinics of North America.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Anil Vachani, Charu Aggarwal, Andrea B. Troxel, 2016, Clinical Cancer Research.

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

W. Hwang, C. Langer, J. Rosenbaum, 2019, JCO precision oncology.

An aggressive radio-resistant papillary thyroid cancer.

C. Langer, R. Mehta, B. Negin, 2008, Clinical advances in hematology & oncology : H&O.

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2014 .

ACR Appropriateness Criteria® Radiation Therapy for Small-Cell Lung Cancer

Joe Y. Chang, K. Rosenzweig, I. Chetty, 2013, American journal of clinical oncology.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

J. Lunceford, M. Ayers, Ying Cheng, 2019, Annals of Oncology.

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

R. Ozols, P. Engstrom, S. Litwin, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data

T. Fojo, S. Bates, C. Langer, 2018, Cancer.

Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594

H. Wakelee, J. Schiller, C. Langer, 2006, Journal of Thoracic Oncology.

Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.

M. Socinski, C. Langer, 1999, Seminars in oncology.

Longitudinal predictors of continued tobacco use among patients diagnosed with cancer

Suzanne M. Miller, B. Movsas, J. Ridge, 2003, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Elderly patients with lung cancer: Biases and evidence

C. Langer, 2002, Current treatment options in oncology.

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

S. Novello, M. Dolled-Filhart, L. Paz-Ares, 2012, British Journal of Cancer.

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

S. Novello, M. Dolled-Filhart, L. Paz-Ares, 2010, British Journal of Cancer.

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Keunchil Park, S. Novello, M. Krzakowski, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.

C. Langer, F. Ottery, J. Hoffman, 2001, Nutrition.

ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.

Joe Y. Chang, K. Rosenzweig, I. Chetty, 2009, Journal of the American College of Radiology : JACR.

Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.

G. Scagliotti, N. Hanna, C. Langer, 2012, Clinical lung cancer.

Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.

C. Langer, J. Weiss, T. Evans, 2010, Clinical lung cancer.

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria

L. Krug, C. Langer, G. Blumenthal, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.

S. Litwin, P. O'dwyer, C. Langer, 1991, European journal of cancer.

The Emerging Role of Cetuximab in Head and Neck Cancer: A 2007 Perspective

C. Langer, I. Astsaturov, R. Panikkar, 2008, Cancer investigation.

Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.

C. Langer, 2011, P & T : a peer-reviewed journal for formulary management.

Staging and prognosis in lung cancer: making the complex accessible.

C. Langer, Corey J. Langer, C. Langer, 2001, Cancer treatment and research.

Etirinotecan Pegol (NKTR‐102) in Third‐line Treatment of Patients With Metastatic or Recurrent Non–Small‐cell Lung Cancer: Results of a Phase II Study

W. Hwang, C. Langer, R. Cohen, 2017, Clinical lung cancer.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

T. Clackson, A. Shaw, S. Gettinger, 2016, The Lancet. Oncology.

PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.

C. Langer, S. Bagley, J. Bauml, 2015, Clinical advances in hematology & oncology : H&O.

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2015, Clinical lung cancer.

Recent advances in the management of advanced non–small-cell lung cancer

C. Langer, C. Aggarwal, 2013 .

Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

Adrian V. Lee, S. McDonald, D. Rimm, 2010, Clinical Cancer Research.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

C. Obasaju, P. Jänne, P. Fidias, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer

C. Langer, C. Aggarwal, 2012, Current opinion in oncology.

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

R. Gray, S. Ramalingam, J. Schiller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small cell lung cancer.

D. Ettinger, M. Kris, G. Bepler, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).

M. Socinski, R. Crowell, C. Langer, 2007, Chest.

Practice Guidelines ( 2 nd Edition ) Stage IV : ACCP Evidence-Based Clinical Treatment of Non-small Cell Lung Cancer

M. Socinski, R. Crowell, C. Langer, 2007 .

First-line chemotherapy for NSCLC: an overview of relevant trials.

C. Langer, C. Belani, 2002, Lung cancer.

Irinotecan/Taxane combinations in advanced non-small-cell lung cancer.

C. Langer, 2002, Clinical lung cancer.

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

David Cella, J. Manola, D. Cella, 2002, Journal of the National Cancer Institute.

Targeted molecular mechanisms of epoetin alfa.

F. Hirsch, C. Langer, N. Thatcher, 2003, Lung cancer.

Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).

M. Millenson, R. Ozols, S. Litwin, 2000, European journal of cancer.

Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

K. Ang, W. Curran, E. Horwitz, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring biomarkers in head and neck cancer

C. Langer, 2012, Cancer.

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

C. Faivre-Finn, S. Senan, L. Paz-Ares, 2020, Lung cancer.

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Ying Cheng, B. Halmos, H. Borghaei, 2020, Cancer.

Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

C. Simone, J. Bradley, S. Gettinger, 2020, JAMA oncology.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.

C. Simone, S. Hahn, A. Maity, 2019, JAMA oncology.

Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).

R. Speck, C. Langer, W. Lenderking, 2019, Future oncology.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2019, Lung cancer.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

L. Sequist, H. Borghaei, A. Patnaik, 2018, Lung cancer.

The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer

G. Oster, T. Delea, J. McKiernan, 2005, Oncology.

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.

C. Langer, R. Natale, 2005, Seminars in oncology.

A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501)

Sigui Li, J. Schiller, C. Langer, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?

D. Ettinger, R. Komaki, B. Movsas, 2005, Lung cancer.

Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

C. Langer, 2012, Clinical advances in hematology & oncology : H&O.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

M. Lacouture, C. Langer, C. Chu, 2018, The oncologist.

Treatment of Lung Cancer in the Elderly Patient

C. Langer, J. Weiss, 2013, Seminars in Respiratory and Critical Care Medicine.

Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences

M. Socinski, C. Langer, 2011 .

Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.

S. Litwin, L. Weiner, C. Langer, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A bupropion smoking cessation clinical trial for cancer patients

J. Ridge, C. Langer, F. Leone, 2010, Cancer Causes & Control.

J. Ridge, C. Langer, R. Schnoll, 2009, Cancer Causes & Control.

Correlates of tobacco use among smokers and recent quitters diagnosed with cancer.

Suzanne M. Miller, B. Movsas, J. Ridge, 2002, Patient education and counseling.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

M. Socinski, K. O'Byrne, J. Singer, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small cell lung cancer clinical practice guidelines in oncology.

D. Ettinger, J. Crawford, F. Fossella, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.

J. Soria, C. Langer, 2010, Clinical lung cancer.

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

R. Komaki, B. Movsas, Colum J Smith, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study.

C. Simone, C. Langer, M. Corradetti, 2015, Practical radiation oncology.

Utilization of supportive and palliative care services among oncology outpatients at one academic cancer center: determinants of use and barriers to access.

Jinbo Chen, C. Langer, J. Mao, 2012, Journal of palliative medicine.

Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

C. Langer, Janet E Brown, R. Cook, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

C. Langer, A. Vachani, R. Cohen, 2015, Oncotarget.

Radiologic Pseudoprogression during Anti–PD‐1 Therapy for Advanced Non–Small Cell Lung Cancer

Sharyn I. Katz, C. Simone, C. Langer, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.

C. Langer, M. Jahanzeb, P. Baumann, 2020, Clinical lung cancer.

P53 Alteration in Oral Tongue Cancer is Not Significantly Associated with Age at Diagnosis or Tobacco Exposure

A. Hanlon, J. Ridge, C. Langer, 2005, Tumori.

Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients.

A. Hanlon, R. Padmore, J. Ridge, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.

G. Scagliotti, C. Gridelli, C. Langer, 2012, Clinical lung cancer.

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.

W. Hwang, C. Langer, R. Verona, 2020, Lung cancer.

Chapter 44 – Non–Small Cell Lung Cancer

C. Langer, H. Wagner, 2016 .

Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.

K. Rosenzweig, W. Curran, H. Choy, 2015, Practical radiation oncology.

ACR Appropriateness Criteria® Postoperative Adjuvant Therapy in Non-Small Cell Lung Cancer

Joe Y. Chang, K. Rosenzweig, B. Movsas, 2011, American journal of clinical oncology.

Resectable Non-Small Cell Lung Cancer in the Elderly

C. Langer, 2008, Drugs & aging.

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.

A. Argiris, B. Murphy, C. Langer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Lung Cancer During the COVID-19 Pandemic.

S. Feigenberg, L. Shulman, A. Berman, 2020, JCO oncology practice.

Systemic therapy for elderly patients with non–small cell lung cancer: Where do we stand in 2019?

C. Langer, C. Aggarwal, 2020, Cancer.

The 2010 Meeting of the American Society of Clinical Oncology

D. Gandara, C. Langer, P. Lara, 2010 .

Combined modality treatment of laryngeal squamous cell carcinoma

C. Langer, J. Devlin, 2007, Expert review of anticancer therapy.

Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): Long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801

Benjamin Movsas, Nicos Nicolaou, R. Komaki, 2007 .

Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy

Eun Jeong Min, K. Cengel, S. Feigenberg, 2020 .

Multi‐Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non–Small Cell Lung Cancer

C. Simone, S. Hahn, A. Berman, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.

W. Curran, R. Komaki, W. Sause, 2005, International journal of radiation oncology, biology, physics.

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

J. Hainsworth, K. Pierce, C. Langer, 2007, Cancer Chemotherapy and Pharmacology.

Emerging Immunotherapies in the Treatment of Non–small Cell Lung Cancer (NSCLC): The Role of Immune Checkpoint Inhibitors

C. Langer, 2015, American journal of clinical oncology.

Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.

Benjamin Movsas, Maria Werner-Wasik, Nicos Nicolaou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.

M. Mehta, C. Langer, H. Robins, 2014, Clinical lung cancer.

Prophylactic Cranial Irradiation in Extensive-Stage Small Cell Lung Cancer

M. Heskel, C. Simone, C. Langer, 2013 .

P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC): Topic: IT

C. Langer, A. Vachani, R. Cohen, 2017 .

Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.

D. Carbone, Y. Shyr, C. Langer, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

C. Obasaju, P. Jänne, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.

W. Curran, P. Rubin, L. Coia, 2000, International journal of radiation oncology, biology, physics.

Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.

M. Millenson, C. Langer, J. Babb, 2002, Clinical lung cancer.

Complementary and alternative medicine use and benefit finding among cancer patients.

C. Langer, D. Valentine, J. Mao, 2013, Journal of alternative and complementary medicine.

49 Paclitaxel (P) by 1 or 24 hour (HR) infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma (NSCLC): A comparative analysis

R. Ozols, C. Langer, C. McAleer, 1997 .

Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.

C. Langer, Corey J Langer, 2004, International journal of radiation oncology, biology, physics.

Role of targeted therapy in non-small cell lung cancer: hype or hope?

C. Langer, 2003, Expert review of anticancer therapy.

Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey

C. Langer, S. Garland, T. Evans, 2014, Supportive Care in Cancer.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Edward S. Kim, H. Groen, E. Smit, 2018 .

Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.

L. Weiner, C. Langer, R. Comis, 1995, Cancer investigation.

Acupuncture for Dyspnea in Lung Cancer

C. Simone, C. Langer, J. Mao, 2016, Integrative cancer therapies.

Patients with non-small cell lung cancer and poor performance status: a significant population with limited data.

C. Langer, R. Lilenbaum, 2004, Seminars in oncology.

79 Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel

A. Barsevick, C. Langer, D. Bruner, 1997 .

The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients.

C. Langer, J. Devlin, 2007, Clinical advances in hematology & oncology : H&O.

Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2015 .

Targeted therapy in head and neck cancer

C. Langer, 2008, Cancer.

Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline

K. Rosenzweig, A. Bezjak, J. Bradley, 2011, Practical radiation oncology.

International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.

A. Bezjak, G. Rodrigues, B. Movsas, 2010, Clinical lung cancer.

Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.

A. Bezjak, G. Rodrigues, B. Movsas, 2012, Clinical lung cancer.

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

A. Tafreshi, Ying Cheng, L. Paz-Ares, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The use of varenicline to treat nicotine dependence among patients with cancer

B. Hitsman, C. Langer, F. Leone, 2017, Psycho-oncology.

315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

J. Krauss, R. Yaeger, M. Fakih, 2022, Annals of Oncology.

Processes of change related to smoking behavior among cancer patients.

Suzanne M. Miller, B. Movsas, J. Ridge, 2002, Cancer practice.

Evaluation and management of elderly patients with lung cancer.

B. Movsas, C. Langer, E. Gore, 2012, Seminars in radiation oncology.

Safety and ef fi cacy of weekly nab ®-paclitaxel in combination with carboplatin as fi rst-line therapy in elderly patients with advanced non-small-cell lung cancer

Wang, M. Socinski, S. Dakhil, 2022 .

Image of the month. A hole in the heart.

C. Langer, A. Lin, J. Weiss, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.

R. Komaki, B. Movsas, S. Swann, 2008, International journal of radiation oncology, biology, physics.

A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence

B. Hitsman, C. Langer, Su Fen Lubitz, 2019, Psycho-oncology.

A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients

Suzanne M. Miller, C. Lerman, J. Ridge, 2005, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer

M. Millenson, A. Hanlon, S. Feigenberg, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.

R. Komaki, L. Mell, A. Mundt, 2007, International journal of radiation oncology, biology, physics.

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.

L. Recht, M. Mehta, Jennifer A. Smith, 2009, International journal of radiation oncology, biology, physics.

Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.

Nandita Mitra, Jarod Finlay, Eli Glatstein, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response

M. Rosen, S. Hahn, A. Maity, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.

C. Langer, J. Kucharczuk, N. Mitra, 2012, International journal of radiation oncology, biology, physics.

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.

J. Bradley, R. Komaki, Y. Lawrence, 2013, Lung cancer.

ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung.

Joe Y. Chang, K. Rosenzweig, B. Movsas, 2010, International journal of radiation oncology, biology, physics.

Surgical Patterns of Care in Operable Lung Carcinoma Treated with Radiation

Joe Y. Chang, R. Komaki, B. Movsas, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer committee

D. Ettinger, R. Munden, R. Komaki, 2001 .

The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancer.

C. Langer, 2003, Clinical lung cancer.

3. Stage-directed treatment guidelines

B. Movsas, C. Langer, C. Dresler, 1996 .

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited‐Stage Small‐Cell Lung Cancer

C. Simone, K. Cengel, C. Langer, 2017, Clinical Lung Cancer.

Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery.

H. Borghaei, R. Mehra, C. Langer, 2014, Cancer control : journal of the Moffitt Cancer Center.

Patterns of care survey (PCS) in locally advanced non-small cell lung cancer (LA-NSCLC) and limited small cell lung cancer (LD-SCLC): how well does current practice follow the literature?

D. Ettinger, R. Komaki, B. Movsas, 2003 .

MA06.01 Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer

K. Cengel, S. Feigenberg, A. Berman, 2021, Journal of Thoracic Oncology.

Induction or neoadjuvant therapy in resectable non-small cell lung cancer.

C. Langer, 1999, Seminars in oncology.

Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.

C. Simone, C. Langer, R. Rengan, 2014, Clinical lung cancer.

Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer

Nandita Mitra, Charles B Simone, Daniel A Pryma, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Influence of Gender, Race, and Marital Status on Survival in Lung Cancer Patients: Analysis of Radiation Therapy Oncology Group Trials

W. Curran, J. Coyne, H. Choy, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Influence of Gender, Race, and Marital Status on Survival in Lung Cancer Patients: Meta-analysis of Radiation Therapy Oncology Group (RTOG) Trials

W. Curran, J. Coyne, H. Choy, 2009 .

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

M. Vangel, P. Stephenson, A. Thor, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer

M. Socinski, S. Ramalingam, J. Schiller, 2015, American journal of clinical oncology.

Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group

S. Nair, C. Langer, R. Cohen, 2004, Cancer investigation.

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer.

F. Hirsch, C. Langer, F. Hirsch, 2004, Seminars in oncology.

A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.

R. Herbst, S. Ramalingam, P. Baas, 2014 .

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

Does salvage therapy influence outcome?

C. Langer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage therapy with gemcitabine (Gem) in advanced non-small cell lung carcinoma (NSCLC) progressing after platinum-taxane chemotherapy

M. Millenson, S. Litwin, C. Langer, 2000 .

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

L. Sequist, H. Borghaei, A. Patnaik, 2016 .

Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study.

D. Cella, M. Golant, C. Langer, 2014, The Journal of community and supportive oncology.

CT-2103: emerging utility and therapy for solid tumours

C. Langer, 2004, Expert opinion on investigational drugs.

Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.

B. Movsas, C. Langer, M. Werner-Wasik, 2005, Seminars in oncology.

Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.

K. Cengel, S. Feigenberg, A. Berman, 2023, Clinical lung cancer.

How Patients View Lung Cancer Screening. The Role of Uncertainty in Medical Decision Making.

L. Fraenkel, C. Simone, C. Langer, 2016, Annals of the American Thoracic Society.

Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (Tx): Implications of ECOG 5592

J. Manola, Douglas B. Johnson, C. Langer, 2000 .

Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience.

R. Livingston, C. Langer, M. Green, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

S. Novello, L. Paz-Ares, C. Langer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.

W. Curran, B. Movsas, C. Langer, 1997, Seminars in oncology.

Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature.

C. Langer, J. Devlin, 2007, Clinical lung cancer.

Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213.

Benjamin Movsas, Hak Choy, Kyounghwa Bae, 2011, Clinical lung cancer.

Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.

Sharyn I. Katz, M. Zauderer, K. Cengel, 2023, JAMA network open.

Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer

M. Socinski, C. Langer, Y. Oh, 2008 .

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.

C. Langer, E. Sherman, R. Somer, 2008, Clinical lung cancer.

Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.

D. Ettinger, W. Curran, H. Choy, 2012, International journal of radiation oncology, biology, physics.

Chemotherapy for the Lungs

C. Langer, J. Weiss, 2013 .

1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA.

T. Clackson, A. Shaw, S. Gettinger, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.

Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC.

Eun Jeong Min, K. Cengel, S. Feigenberg, 2019, International journal of radiation oncology, biology, physics.

OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial

Edward S. Kim, Dohoung Kim, S. Gettinger, 2017 .

1344PBrigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial

A. Shaw, S. Gettinger, R. Camidge, 2017 .

56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results

A. Shaw, S. Gettinger, R. Salgia, 2016 .

Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?

C. Langer, 2011, Clinical lung cancer.

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck

H. Quon, C. Langer, J. Bauman, 2013, Experimental and therapeutic medicine.

O-52 ECOG 1599: Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC

P. Stephenson, J. Schiller, C. Langer, 2003 .

Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.

P. O'dwyer, C. Langer, N. Rosenblum, 1991, Gynecologic oncology.

Successful coronary artery bypass grafting after concurrent chemoradiation therapy in a patient with non-small-cell lung cancer: case report and review of the literature.

C. Langer, S. Ibrahim, 2006, Clinical lung cancer.

Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program

C. Langer, F. Leone, R. Schnoll, 2011, Acta oncologica.

A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99

C. Langer, P. Loehrer, W. Tester, 2008 .

Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database

S. Singhal, C. Langer, F. Azari, 2023, Cancer medicine.

Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.

M. Millenson, R. Ozols, S. Litwin, 1997, Seminars in oncology.

Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.

Hao Wang, C. Langer, G. Hudes, 2006, The journal of supportive oncology.

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.

M. Berger, P. Zatloukal, C. Langer, 2014, Lung cancer.

Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

L. Sequist, H. Borghaei, S. Jalal, 2016 .

Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+)advanced non-small cell lung cancer (nsclc): early analysis of e2598

M. Vangel, S. Adak, Douglas B. Johnson, 2001 .

Acute Encephalopathy Attributed to 5‐FU

C. Langer, A. Shaer, D. Roby, 1996, Pharmacotherapy.

Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC).

M. Millenson, H. Borghaei, C. Langer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer

Sharyn I. Katz, K. Cengel, S. Feigenberg, 2023, Advances in radiation oncology.

Caring for the Older Population With Advanced Lung Cancer.

C. Langer, C. Presley, C. Reynolds, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.

W. Hwang, C. Langer, R. Cohen, 2022, Clinical lung cancer.

Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC

S. Gettinger, M. Ahn, D. Camidge, 2018 .

Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (M

A. Rossi, C. Gridelli, C. Langer, 2011, Clinical lung cancer.

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2016 .

Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.

A. Shaw, S. Gettinger, R. Salgia, 2016 .

Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)‐positive (ALK+) non‐small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330

A. Shaw, S. Gettinger, R. Salgia, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach

P. O'dwyer, C. Langer, R. Catalano, 2004, Cancer Chemotherapy and Pharmacology.

Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity

S. Singhal, C. Langer, S. Albelda, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

D. Torigian, A. Troxel, C. Langer, 2017, Lung cancer.

Phase II Study of Paclitaxel and Cisplatin in Combination with Split Course Concomitant Hyperfractionated Re-Irradiation in Patients with Recurrent Squamous Cell Cancer of the Head and Neck: Results of RTOG 99-11

K. Ang, W. Curran, E. Horwitz, 2005 .

Assessing patient accrual to cooperative group lung cancer trials: why are rates disappointing?

Charles R. Thomas, C. Langer, B. Lally, 2011, Journal of Thoracic Oncology.

Locally Advanced, Unresectable Non–Small-Cell Lung Cancer

R. Govindan, C. Langer, Facp., 2007 .

CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.

C. Langer, 2004, Clinical lung cancer.

Effectiveness versus convenience: patient preferences for an erythropoietic agent to treat cancer-related anemia*

S. Bolge, C. Langer, M. Zilberberg, 2007, Current medical research and opinion.

Phase I study of irinotecan (CPT-11), cisplatin (cDDP) and radical thoracic radiation (TRT) in the treatment of locally advanced non-small cell lung carcinoma (NSCLC)

M. Millenson, B. Movsas, C. Langer, 2000 .

Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation

L. Coia, E. Sauter, C. Langer, 1995, Journal of surgical oncology.

Response to Temozolomide in Second-Line Treatment of Recurrent Nonsmall Cell Lung Carcinoma: Case Report

C. Langer, R. Somer, 2005, Cancer investigation.

Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer

C. Langer, B. Milcarek, J. Stevenson, 2012, Cancer.

2006 Highlights From: 7th International Lung Cancer Congress Workshop Maui, HI; June 28-July 1, 2006

K. Yoneda, D. Gandara, C. Langer, 2006 .

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.

M. Socinski, S. Dakhil, C. Langer, 2013 .

Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.

C. Langer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can Mol Sub Fac

Adrian V. Lee, S. McDonald, D. Rimm, 2010 .

Thymic hyperplasia with hemorrhage simulating recurrent hodgkin disease after chemotherapy‐Induced complete remission

C. Langer, R. Schiffman, S. Erner, 2022 .

ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.

Joe Y. Chang, K. Rosenzweig, I. Chetty, 2009, Journal of the American College of Radiology : JACR.

OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update

L. Sequist, H. Borghaei, S. Jalal, 2017 .

First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Low Morbidity and Excellent Local Control using Image Guided Stereotactic Body Radiotherapy (IGSBRT) for Lung Tumors

S. Feigenberg, B. Movsas, C. Langer, 2008 .

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer

C. Langer, R. Cohen, R. Amaravadi, 2023, The oncologist.

Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: The case of the United Kingdom (UK)

C. Langer, M. Botteman, J. Brandman, 2007 .

Epoetin alfa 60,000 U QW followed by 80,000 U Q3W maintenance in patients with anemia and cancer receiving chemotherapy

C. Langer, A. Grosbach, D. Williams, 2004 .

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

J. Milanowski, J. Aerts, R. Ramlau, 2023, Journal of Clinical Oncology.

MA25.04 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Outcomes After Pembrolizumab Based First Line Therapy in Metastatic NSCLC

C. Langer, S. Yee, E. Carpenter, 2019, Journal of Thoracic Oncology.

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial

Edward S. Kim, H. Groen, S. Gettinger, 2019, Annals of Oncology.

Irinotecan Therapy for Small-Cell Lung Cancer

C. Langer, 2017 .

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

W. Hwang, L. Shulman, C. Langer, 2023, JCO Precision Oncology.

Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Use of Local Therapy in Patients with Oligoprogression

K. Cengel, S. Feigenberg, C. Langer, 2023, Clinical Lung Cancer.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

Sharyn I. Katz, C. Simone, D. Heitjan, 2016, Clinical Cancer Research.

W. Curran, R. Jeraj, J. Bradley, 2017, Clinical lung cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.

W. Hwang, C. Langer, R. Cohen, 2023, JAMA oncology.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

EGFR inhibition and other targeted therapies in NSCLC

C. Langer, 2012 .

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

R. Greil, J. Milanowski, J. Aerts, 2023, The Lancet. Oncology.

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

R. Herbst, J. Nemunaitis, F. Kabbinavar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.